Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14696015 | 1.00 | S1PR1 (0.77) | S1PR1ALDH1A1MAPK1SMN1; SMN2MAPT | |
| SCHEMBL2577241 | 1.00 | S1PR1 (0.77) | S1PR1ALDH1A1MAPK1SMN1; SMN2MAPT | |
| SCHEMBL14696384 | 0.92 | S1PR1 (0.79) | S1PR1SMN1; SMN2CARM1 | |
| SCHEMBL14696388 | 0.92 | S1PR1 (0.79) | S1PR1SMN1; SMN2CARM1 | |
| SCHEMBL14696386 | 0.92 | S1PR1 (0.79) | S1PR1SMN1; SMN2CARM1 | |
| SCHEMBL2575478 | 0.89 | S1PR1 (0.78) | S1PR1CARM1 | |
| SCHEMBL2579533 | 0.89 | S1PR1 (0.78) | S1PR1CARM1 | |
| SCHEMBL14696422 | 0.89 | S1PR1 (0.75) | S1PR1CARM1 | |
| SCHEMBL2576157 | 0.87 | S1PR1 (0.86) | S1PR1 | |
| SCHEMBL2574931 | 0.87 | S1PR1 (1.00) | S1PR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835470-B2 | Mandelamide heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-16 | — | — | US | disclosed |
| US-20130045964-A1 | MANDELAMIDE HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045964-A1 | MANDELAMIDE HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR5 | S1PR1 1/4885ALDH1A1 2189/4885MAPK1 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.